

Northern, Eastern & Western Devon Clinical Commissioning Group
South Devon and Torbay Clinical Commissioning Group

Notes of the meeting of the South and West Devon Formulary Interface Group

Tuesday 13th September 2013 - 2pm – 4pm

The Watermark, Erme Court, Leonards Road, Ivybridge PL21 0SZ

Present:	Chris Roome(CR) – Chair Phil Melliush (PM) – GP Larissa Sullivan (LS) – Interface Pharmacist Sarah Marner (SM) – Interface Pharmacist Carol Webb (CW) – Joint Formularies Technician Margaret Hinchliffe (MH) Jeremy Morris (JM) – Formulary Pharmacist Gareth Franklin (GF) – Clinical Guidance Manager Iain Roberts (IR) – Lead MO Pharmacist Elena Mercer (EM) – Formulary Pharmacist Petrina Trueman (PT) – Joint Formularies Pharmacist Andrew Gunatilleke (AG1) – Consultant, Chair SDNT DTC Paul Humphriss (PH1) – Head of Medicines Management Paul Hughes (PH2) – Deputy Head of Prescribing	NEW Devon CCG South Devon & Torbay CCG NEW Devon CCG NEW Devon CCG NEW Devon CCG Lay member Plymouth Hospitals NHS Trust NEW Devon CCG South Devon & Torbay CCG South Devon NHS Trust NEW Devon CCG South Devon NHS Trust South Devon NHS Trust Kernow CCG
Invited:	Theresa Mitchell - Tissue Viability Specialist Nurse Rebecca Bell – Medicines Optimisation Pharmacist	Plymouth Community Healthcare South Devon & Torbay CCG
Apologies	Mike Finnegan (MF) – Consultant, Chair PHNT DTC Jamie Fulton (JF) - Consultant Amanda Gulbranson (AG2)- Clinical Effectiveness Lead Sue Benham – Community Nurse Phillipa Hawkins (PH3) – Modern Matron Keith Gillespie (KG) - GP Mark Stone (MS) – Community Pharmacist	Plymouth Hospitals NHS Trust Plymouth Hospitals NHS Trust Devon Partnership Trust South Devon & Torbay CCG South Devon & Torbay CCG NEW Devon CCG Devon LPC
1	Welcome: The Chair welcomed everyone. Apologies as noted above.	
2	Notes of last meeting 16th July 2013: These were noted and agreed.	
3	Action log: <ul style="list-style-type: none"> ● Revised Osteoporosis pathway: Revised osteoporosis being discussed by specialists across Devon- to be brought to future meeting. Action: To bring a revised osteoporosis pathway to future meeting ● Denosumab prescribing data: The Committee noted that use of denosumab was relatively low in primary care but would appear to be increasing as might have been expected following restrictions on the use of strontium ● Rivaroxaban DVT guidance: The wording has been agreed with specialists in South Devon. Guidance to be added to the SDJF. This provides very similar guidance in Plymouth and South Devon 	

Northern, Eastern & Western Devon Clinical Commissioning Group
South Devon and Torbay Clinical Commissioning Group

Action: LS to send agreed statement to CW

- **CDF cohort drugs in the formulary:** It was suggested that the Cancer Drug Fund Cohort drugs should be recorded in the formulary but presented in the standard text font colour (black), to differentiate them from standard 'formulary' drugs, with a note explaining their use. Any new CDF cohort drugs to be included in the Recent Drug Approvals standing agenda item. The Committee discussed the benefits of specifying the commissioner in the local formularies (i.e. NHS England, CCG). It was agreed that this suggestion would be reviewed when an up-to-date and clearly defined list was published of NHSE responsibility.
- **Dapagliflozin TA:** GF updated the Committee on the type 2 diabetes pathways and the recent NICE TA for dapagliflozin. Both the Plymouth and South Devon formularies include complex treatment pathways for type 2 diabetes, these will be reviewed as part of the merger of the Endocrine chapter. Suggesting that dapagliflozin be added to both formularies as per NICE guidance, with a wider T2DM pathway discussed at the future FIG meeting. Comment from the meeting questioned the inclusion of dapagliflozin as a second-line and not specialist drug, noting that this is a first in class agent. The Committee agreed with this suggestion, emphasising that referring to a treatment pathway developed by local specialists may be sufficient to support specialist use.

Action: GF to contact specialists in Derriford and Torbay to finalise formulary entry

- **Mirabegron TA:** The Committee discussed a draft formulary entry agreed by specialists in both trust, placing mirabegron as a specialist drug. Management of overactive bladder to be discussed at a future FIG meeting following publication of new NICE Clinical Guidance.

Action: CW to added mirabegron to both formularies

- **COPD pathway:** Place in pathway of new COPD drugs agreed with specialists in each trust. The Committee agreed that the decision to switch between long-acting bronchodilators would be based on individual clinical judgement and a note would not be added to the formulary.

4 Dressings formulary merger update

Theresa Mitchell updated the Committee on work to align the dressing formularies across South and West Devon. The CQUIN target for South Devon was discussed and it was noted that this would not be a barrier for product selection / alignment. Given this it was felt that there was scope for further commonality in product choice. This project began in June 2013 and is expected to take 6-9 months.

Action: An update on the project to be given to the FIG after the next dressings meeting.

5 Antimicrobial merged section

Graham Parsons (Medicines Optimisation Pharmacist, NEW Devon CCG (Western Locality)) has reviewed the primary care antimicrobial guidance for the new South-West Joint Formulary, working with Dr Jim Grieg in Derriford and Dr Paul Turner in Torbay. GF summarised the key points of the review to the Committee. GF confirmed that the appropriate individual specialities in each trust would be sent the sections of the antimicrobial guidance relevant to their practice for comment. It was noted a handful of sections which needed further work with specialists.

Specific points from review:

- PH1 to raise diabetic foot guidance with podiatry.
- GF to send guidance to PH1 and SM to assess impact on current PGDs.

Northern, Eastern & Western Devon Clinical Commissioning Group
South Devon and Torbay Clinical Commissioning Group

- GF to check if stool sampling was discussed for C diff.
- GF to confirm place of ciprofloxacin for prostatitis.
- Genital herpes: on-going management often carried out by GPs - to raise this with specialists.
- GF to ensure general guidance on first page is consistent with the rest of the document.

Action: GF to bring formatted guidance to next meeting.

6 Terms of Reference

The Committee discussed the draft ToR. The number of clinicians on the committee was discussed, the final number of GPs to be determined by the individual areas. A clinical chair to be nominated at a future date. Exact membership of the committee was discussed, along with the relationship of FIG and other groups working across Devon. Representative from Kernow CCG to be added to the membership list. The exact name of the Formulary Group was discussed- it was agreed that these discussions should be deferred for a future date.

Action: updated ToR to be brought to next meeting

7 Dermatology revised shared care (Western Locality)

CW introduced six updated Dermatology shared care guidelines, explaining that this work began at the PCT in late 2012. Current guidelines have been reviewed with specialists in Derriford and agreed. It was suggested that the LMC should be made aware if the guidelines involve service change. Due to the absence of GPs from the Plymouth area the group suggested that Chair's approval could occur after liaison with KG.

Action: CR to send to KG for agreement

8 GLP-1 Patient leaflet

LS introduced a new GLP-1 patient information leaflet developed by specialists in Torbay and Derriford. The Committee felt that it was not appropriate for the FIG to sign-off patient information leaflets developed by secondary care but was very happy to have sight of drafts and be given the opportunity for comment. A link to be added to the new formulary to the patient leaflets where available.

9 Intravenous iron review

Item deferred

10 Recent drug approvals (including NICE)

Noted. Details of drugs approved by the Clinical Policy Committee to be emailed after the meeting.

11 Referral Pathway Tool

Details to be sent by email.

12 MHRA Drug Safety Update – July, August

Drug Safety Updates were noted.

The guidance on codeine in children was considered - details to be picked up by pharmacists leading the review of the pain chapter.

Updated metoclopramide dose to be included in merged formulary

Action: CW to ensure correct dose in new formulary platform

13 Formulary merger update

Work plan noted.

Next meeting: Friday 11th October 2013 2pm – 4:30pm The Watermark, Ivybridge PL21 0SZ

Northern, Eastern & Western Devon Clinical Commissioning Group
South Devon and Torbay Clinical Commissioning Group

South and West Devon Formulary Group – Action log			
Date	Action	Responsible	Completed
June 2013	To bring a revised osteoporosis pathway to future meeting	GF	
Sept 2013	Rivaroxaban DVT guidance to be added to SDJF	LS/CW	
Sept 2013	Dapagliflozin formulary entry to be agreed with specialists	GF	Completed
Sept 2013	Mirabegron to be added to the formularies as a specialist drug	CW	Completed
Sept 2013	An update on the dressings project to be given to the meeting after the next dressings meeting	TM	
Sept 2013	Antibacterial – specific points for further information (see notes above).	GF	On agenda
Sept 2013	Updated ToR for discussion	GF	On agenda
Sept 2013	PAJF Dermatology shared care, to send to KG for agreement	CR/CW	Completed
Sept 2013	MHRA Drug Safety Update: to ensure metoclopramide doses are reflected in the new formulary	CW	